- Medicare Part D has traditionally excluded drugs used for weight loss or cosmetic purposes
- Wegovy’s FDA-approved cardiovascular indication creates a potential exception to this exclusion
- Coverage is evolving rapidly — some Part D plans have begun covering Wegovy for cardiovascular risk reduction
- Eligibility for the cardiovascular pathway requires established cardiovascular disease along with overweight or obesity
Important Notice
PEAK Wellness & Aesthetics does not accept Medicare as primary insurance for new patients. This article is provided as an educational resource about Medicare coverage for Wegovy. If you are a Medicare beneficiary interested in Wegovy, we recommend contacting your Medicare plan directly or speaking with a provider who accepts Medicare. For questions about self-pay options at PEAK, contact us.
Medicare’s traditional exclusion
Medicare Part D includes a statutory exclusion for drugs used for weight loss or weight gain. This exclusion has been in place since the Part D program launched in 2006, and it has historically prevented Medicare beneficiaries from receiving coverage for anti-obesity medications.
The exclusion is not based on whether a medication is effective or medically necessary. It is a categorical rule: if a drug’s primary use is weight management, Part D plans are not required to cover it — and most do not.
This means that medications like Wegovy (semaglutide), Saxenda, and Contrave have generally been unavailable to the more than 65 million Americans enrolled in Medicare, even when prescribed by a clinician for obesity as a chronic disease.
Obesity affects approximately 42% of adults over age 65. The Part D exclusion has left millions of Medicare beneficiaries without access to FDA-approved treatments for a condition that significantly increases their risk of heart disease, stroke, type 2 diabetes, and other serious health problems.
The cardiovascular game-changer
In March 2024, the FDA approved a supplemental indication for Wegovy: the reduction of cardiovascular risk in adults with established cardiovascular disease and either obesity or overweight. This approval was based on the SELECT trial, a landmark study of over 17,000 participants.
This is where the coverage picture changes. The cardiovascular indication is fundamentally different from the weight loss indication. When Wegovy is prescribed to reduce cardiovascular risk, it is not being prescribed for weight loss — it is being prescribed for heart health.
The cardiovascular indication is not a workaround. It is a separate, FDA-approved use of Wegovy for a life-threatening condition — and it may fall outside Medicare’s weight loss exclusion entirely.
The SELECT trial demonstrated that Wegovy reduced the risk of major adverse cardiovascular events — heart attack, stroke, and cardiovascular death — by 20% in patients with established heart disease and overweight or obesity. These results led the FDA to grant the cardiovascular indication, making Wegovy the first GLP-1 receptor agonist approved specifically to reduce heart risk in this population.
Medicare Part D excludes drugs used “for weight loss.” But when Wegovy is prescribed under the cardiovascular indication, it is being used for cardiovascular risk reduction. This distinction is the foundation of the coverage exception.
How the exception works
The logic is straightforward, even if the implementation is complex. Medicare Part D’s statutory exclusion applies to drugs used for weight loss. If Wegovy is prescribed for a non-weight-loss indication — specifically, cardiovascular risk reduction — it may not be subject to the exclusion.
For this exception to apply, several conditions must be met:
- The prescribing indication must be cardiovascular risk reduction — not weight loss, not obesity management. The prescriber must document that Wegovy is being used to reduce the risk of major adverse cardiovascular events.
- The patient must have established cardiovascular disease — a documented history of heart attack, stroke, or peripheral artery disease.
- The patient must have a BMI of 27 or higher — consistent with the FDA-approved labeling for the cardiovascular indication.
- The Part D plan must agree to cover it — CMS has issued guidance clarifying that plans may cover Wegovy under the cardiovascular indication, but individual plans retain discretion over their formularies.
In practice, this means the prescribing clinician plays a critical role. The way the prescription is documented — the indication, the diagnosis codes, the clinical rationale — determines whether the claim is processed as a cardiovascular drug or a weight loss drug.
Who qualifies
The cardiovascular coverage pathway is not available to every Medicare beneficiary who wants Wegovy. Eligibility is specific and based on the FDA-approved labeling for the cardiovascular indication.
To qualify, a patient generally needs:
- Established cardiovascular disease — This means a documented history of at least one of the following: prior heart attack (myocardial infarction), prior stroke (cerebrovascular event), or diagnosed peripheral artery disease (PAD).
- Overweight or obesity — A BMI of 27 or higher, consistent with the SELECT trial enrollment criteria and the FDA-approved indication.
- Medicare Part D enrollment — The patient must be enrolled in a Part D plan that has opted to cover Wegovy under the cardiovascular indication.
Medicare beneficiaries who want Wegovy solely for weight loss — without established cardiovascular disease — do not qualify for the cardiovascular exception. The Part D weight loss exclusion still applies to these patients. Similarly, patients with cardiovascular risk factors but no established cardiovascular disease (for example, hypertension or high cholesterol alone) may not meet the criteria.
Current coverage status
The coverage situation for Wegovy under Medicare is changing rapidly. Here is where things stand:
- CMS guidance. The Centers for Medicare & Medicaid Services has issued guidance indicating that Part D plans may cover Wegovy when prescribed for the cardiovascular indication. This was a significant step, as it confirmed that the cardiovascular use is not subject to the weight loss exclusion.
- Part D plan adoption. Some Part D plans have begun adding Wegovy to their formularies for the cardiovascular indication. However, adoption is not universal. Each plan makes its own formulary decisions, and many plans have not yet added coverage.
- Legislative efforts. The Treat and Reduce Obesity Act has been introduced in Congress multiple times. If passed, it would remove the Part D weight loss exclusion entirely, opening coverage for anti-obesity medications regardless of indication. As of early 2026, the legislation has not been enacted, but it continues to gain bipartisan support.
- Cost considerations. Even when covered, beneficiaries may face significant cost-sharing. Wegovy is a specialty-tier medication on most formularies, which can mean higher copays or coinsurance percentages.
| Coverage scenario | Status |
|---|---|
| Part D — weight loss indication | Excluded by statute |
| Part D — cardiovascular indication | Permitted by CMS; plan-dependent |
| Medicare Advantage with Part D | Some plans covering; varies widely |
| Treat and Reduce Obesity Act | Pending legislation; not yet enacted |
Medicare Advantage plans
Medicare Advantage (MA) plans — also known as Part C — are private insurance plans that contract with Medicare to provide all Part A and Part B benefits, and most also include Part D prescription drug coverage. These plans have more flexibility than Original Medicare in designing their benefits.
Some Medicare Advantage plans have been faster to adopt coverage for Wegovy under the cardiovascular indication. Because MA plans compete for enrollment, some have added Wegovy coverage as a differentiating benefit, particularly in markets with high rates of cardiovascular disease and obesity.
Coverage varies significantly across Medicare Advantage plans. A plan that covers Wegovy in one region may not cover it in another. Prior authorization requirements, formulary tier placement, and cost-sharing structures all differ by plan. The only way to confirm coverage is to check your specific plan’s formulary or contact the plan directly.
If you are considering switching to a Medicare Advantage plan specifically for Wegovy coverage, review the plan’s formulary carefully before enrolling. Confirm that Wegovy is listed, understand the prior authorization requirements, and check what tier it is placed on — this directly affects your out-of-pocket cost.
What to do now
If you are a Medicare beneficiary interested in Wegovy, here are the steps to take:
- Verify your specific plan. Check your Part D or Medicare Advantage plan’s formulary for Wegovy (semaglutide). Look for whether it is listed under the cardiovascular indication specifically. If you cannot find it online, call the number on your Medicare card.
- Review your cardiovascular history. The cardiovascular pathway requires documented established cardiovascular disease. Gather records of any prior heart attacks, strokes, or peripheral artery disease diagnoses.
- Work with a provider who understands the pathway. The way your prescription is written and documented matters. Your clinician must prescribe Wegovy for cardiovascular risk reduction — not for weight loss — and submit the appropriate diagnosis codes and clinical documentation.
- Prepare for prior authorization. Even when a plan covers Wegovy, prior authorization is almost always required. Your clinician will need to submit documentation proving you meet the criteria for the cardiovascular indication.
- Consider your enrollment timing. If your current plan does not cover Wegovy, you may be able to switch to a plan that does during the Annual Enrollment Period (October 15 – December 7) or during a Special Enrollment Period if you qualify.
The difference between a covered prescription and a denied one often comes down to how it is documented. The clinical pathway matters as much as the clinical need.
If you have commercial insurance or TRICARE, PEAK can help you explore Wegovy coverage options including the cardiovascular pathway. We verify your plan’s formulary, document the appropriate clinical indication, and handle prior authorization submissions. Medicare beneficiaries should verify coverage details with their specific Part D plan directly. For questions about self-pay options, contact our team.
